China
Africa
Explore chapters and articles related to this topic
Radiochemistry for Preclinical Imaging Studies
Published in George C. Kagadis, Nancy L. Ford, Dimitrios N. Karnabatidis, George K. Loudos, Handbook of Small Animal Imaging, 2018
Variants include DOTA–octreotate (DOTATATE) and edotreotide ((DOTA0-Phe1-Tyr3)octreotide, or DOTATOC). These can be considered as theranostic companions, for example, to 90Y-DOTA-TOC and 177Lu-DOTA-TATE therapeutics.
Peptide receptor radionuclide therapy in neuroendocrine neoplasms and related tumors: from fundamentals to personalization and the newer experimental approaches
Published in Expert Review of Precision Medicine and Drug Development, 2023
d) Currently ongoing phase III prospective trial (COMPLETE) using 177Lu-Edotreotide aka DOTATOC, similar octreotide analogue with different SSTR subtype binding affinities. This trial is randomized patients open-label, study to evaluate the efficacy and safety of n.c.a. 177Lu-Edotreotide PRRT compared to mTOR inhibitor everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+) GEP-NETs. The study is currently recruiting patients in 14 countries. As part of the study, 300 patients with progressive SSTR+ Grade 1 and 2 GEP-NETs are being randomized, of which 200 receive up to 4 cycles of n.c.a. 177Lu-Edotreotide (7.5 GBq/cycle) every 3 months or until the diagnosis of progression, while 100 patients receive 10 mg everolimus daily for 24 months, or until the diagnosis of progression. The overall study duration per patient will be 30 months. The study will provide data for using the peptide DOTATOC, prolonged progression-free survival (PFS) in patients in the n.c.a. 177Lu-Edotreotide arm vs. Everolimus – which will make PRRT evidence stronger and also will provide insights for safety, objective response rates, and overall survival after 5 years follow-up [146]. Another similar study which is currently ongoing that has planned to recruit 200 patients and randomize 1:1 between 6 cycles Lu-177-edotreotide vs standard of care from CAPTEM, everolimus or FOLFOX therapy. Patients will be followed up for PFS and OS [147,148].